Goodwin Procter advised Prime Medicine and Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction, while Davis Polk & Wardwell...
Prime Medicine’s $161.0 Million Common Stock Offering
Arena BioWorks’ Launch
Wilson Sonsini Goodrich & Rosati advised Arena BioWorks on patent and transactional matters. Arena BioWorks announced its launch as a biomedical research institute with a mission...
CARGO Therapeutics’ $281.3 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
Chroma Medicine’s $135 Million Series B Financing
Wilson Sonsini advised Chroma Medicine on the deal. Genomic medicine company Chroma Medicine announced that it had completed a $135 million Series B financing, which was...
Third Rock Ventures’ Investment in CARGO Therapeutics
Orrick advised Third Rock Ventures on the deal while Wilson Sonsini represented CARGO Therapeutics. Third Rock Ventures announced its investment in the $200 million Series A financing...
ATP’s Launch of Ascidian Therapeutics
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
Prime Medicine’s $175 Million IPO
Wilson Sonsini and Honigman advised Prime Medicine on the deal, while Davis Polk advised the joint book-running managers. Prime Medicine, Inc., a biotechnology company committed to...
Marengo Therapeutics’ Partnership with Ipsen
Wilson Sonsini Goodrich & Rosati advised Marengo on the deal. Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated...
Gilead Sciences’ $405 Million Acquisition of MiroBio
Davis Polk & Wardwell, Mayer Brown, and Mishcon de Reya advised Gilead, while Goodwin Procter and Wilson Sonsini Goodrich & Rosati advised MiroBio on the deal....
MiroBio’s $97 Million Series B Financing
Wilson Sonsini Goodrich & Rosati and Goodwin advised MiroBio on the deal. MiroBio, a leader in the development of checkpoint agonists to treat autoimmune diseases, announced...
Galapagos’ Acquisition of CellPoint
Wilson Sonsini Goodrich & Rosati advised CellPoint on the deal. Walder Wyss has advised +ND Capital, while Baker McKenzie advised CellPoint and AboundBio. Galapagos, a fully...
Simcha Therapeutics’ $40 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40...